OTLK Insider Trading Activity and SEC Form 4 Filings
OTLK insider trading summary
Over the past 12 months, insiders at Outlook Therapeutics, Inc. (OTLK) reported 12 open-market purchases worth $15.4M by 8 insiders and no sales on SEC Form 4. Net insider buying was $15.4M.
Latest OTLK insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Aug 14, 2026 | Robert Charles Jahr | Chief Executive Officer | Buy | $0 (151,515 @ $0.00) |
| Aug 14, 2026 | Lawrence A Kenyon | Chief Financial Officer | Buy | $0 (101,010 @ $0.00) |
| Aug 12, 2026 | Ghiath M. Sukhtian | Insider | Buy | $2.5M (2,525,252 @ $0.99) |
| Aug 12, 2026 | GMS Ventures & Investments | Insider | Buy | $2.5M (2,525,252 @ $0.99) |
| Jul 29, 2026 | Faisal Ghiath Sukhtian | Director | Buy | $100K (95,398 @ $1.05) |
| Jun 2, 2026 | Yezan Munther Haddadin | Director | Buy | $24K (29,000 @ $0.83) |
| May 28, 2026 | GMS Ventures & Investments | Insider | Buy | $5.0M (8,539,709 @ $0.59) |
| May 28, 2026 | Ghiath M. Sukhtian | Insider | Buy | $5.0M (8,539,709 @ $0.59) |
| May 27, 2026 | Faisal Ghiath Sukhtian | Director | Buy | $50K (122,174 @ $0.41) |
| May 26, 2026 | Kurt J Hilzinger | Director | Buy | $177K (400,000 @ $0.44) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.